These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 9083792)
1. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Inoue A; Miki S; Seto M; Kikuchi T; Morita S; Ueda H; Misu Y; Nakata Y Eur J Pharmacol; 1997 Feb; 321(1):105-11. PubMed ID: 9083792 [TBL] [Abstract][Full Text] [Related]
2. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Inoue A; Seto M; Sugita S; Hide I; Hirose T; Koga N; Kikuchi T; Nakata Y Brain Res Mol Brain Res; 1998 Apr; 55(2):285-92. PubMed ID: 9582438 [TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049 [TBL] [Abstract][Full Text] [Related]
4. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats. Der-Ghazarian T; Charntikov S; Varela FA; Crawford CA; McDougall SA J Neural Transm (Vienna); 2010 May; 117(5):573-83. PubMed ID: 20372943 [TBL] [Abstract][Full Text] [Related]
5. Antagonistic effects of OPC-14597, a novel antipsychotic drug, on quinpirole- and (-)-sulpiride-induced changes in evoked dopamine release in rat striatal slices. Yamada S; Harano M; Yokoo H; Tanaka M J Pharm Pharmacol; 1997 Feb; 49(2):206-8. PubMed ID: 9055196 [TBL] [Abstract][Full Text] [Related]
6. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741 [TBL] [Abstract][Full Text] [Related]
7. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol. Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390 [TBL] [Abstract][Full Text] [Related]
8. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076 [TBL] [Abstract][Full Text] [Related]
9. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats. Varela FA; Der-Ghazarian T; Lee RJ; Charntikov S; Crawford CA; McDougall SA J Psychopharmacol; 2014 Apr; 28(4):376-86. PubMed ID: 24045880 [TBL] [Abstract][Full Text] [Related]
10. The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain. Shapiro LA; Offord SJ; Ordway GA Brain Res; 1995 Apr; 677(2):250-6. PubMed ID: 7552250 [TBL] [Abstract][Full Text] [Related]
11. Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices. Ishida K; Ohno Y; Ishibashi T; Nakamura M Gen Pharmacol; 1996 Oct; 27(7):1203-7. PubMed ID: 8981068 [TBL] [Abstract][Full Text] [Related]
12. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Han M; Huang XF; Deng C Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization. Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116 [TBL] [Abstract][Full Text] [Related]
14. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416 [TBL] [Abstract][Full Text] [Related]
15. Altered dopamine D2-like receptor binding in rats with behavioral sensitization to quinpirole: effects of pre-treatment with Ro 41-1049. Culver KE; Szechtman H; Levant B Eur J Pharmacol; 2008 Sep; 592(1-3):67-72. PubMed ID: 18644362 [TBL] [Abstract][Full Text] [Related]
16. The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors. Popoli P; Pèzzola A; Torvinen M; Reggio R; Pintor A; Scarchilli L; Fuxe K; Ferré S Neuropsychopharmacology; 2001 Oct; 25(4):505-13. PubMed ID: 11557164 [TBL] [Abstract][Full Text] [Related]
17. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908 [TBL] [Abstract][Full Text] [Related]
18. [How do antipsychotics exert their effects on dopamine receptor subtypes?]. Inoue A; Nakata Y Nihon Yakurigaku Zasshi; 1998 Dec; 112(6):351-61. PubMed ID: 10202760 [TBL] [Abstract][Full Text] [Related]
19. D2 dopamine receptors and modulation of spontaneous acetylcholine (ACh) release from rat striatal synaptosomes. Clos MV; García-Sanz A; Vivas NM; Badia A Br J Pharmacol; 1997 Sep; 122(2):286-90. PubMed ID: 9313937 [TBL] [Abstract][Full Text] [Related]
20. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Urban JD; Vargas GA; von Zastrow M; Mailman RB Neuropsychopharmacology; 2007 Jan; 32(1):67-77. PubMed ID: 16554739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]